Intratibial injection of an anti-doxorubicin monoclonal antibody prevents drug-induced myelotoxicity in mice
1997

Monoclonal Antibody Protects Mice from Doxorubicin Toxicity

Sample size: 94 publication Evidence: high

Author Information

Author(s): D Morelli, S Menard, S Cazzaniga, Ml Colnaghi, A Balsari

Primary Institution: Istituto Nazionale Tumori and University of Milan

Hypothesis

Can the monoclonal antibody MAD11 protect bone marrow from doxorubicin-induced myelotoxicity in mice?

Conclusion

The monoclonal antibody MAD11 effectively protects bone marrow from the toxic effects of doxorubicin without compromising its anti-tumor activity.

Supporting Evidence

  • All mice pretreated with MAD11 survived after receiving a lower dose of doxorubicin.
  • 41% of mice treated with doxorubicin alone died.
  • No deaths were observed in MAD11-treated mice after the initial 6 days at a higher doxorubicin dose.

Takeaway

Researchers found that a special antibody can help protect mice's bone marrow from damage caused by a cancer drug called doxorubicin.

Methodology

Mice were injected with the monoclonal antibody MAD11 in the tibia before receiving doxorubicin, and their survival and bone marrow health were monitored.

Limitations

The study was conducted only in mice, and the long-term effects of the antibody treatment were not assessed.

Participant Demographics

Six- to eight-week-old female BALB/c and C57BL/6 x DBA2 mice.

Statistical Information

P-Value

p<0.0001

Statistical Significance

p<0.002

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication